{"id":"zvs101e","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, ZVS101e reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"ZVS101e is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:28.715Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07307469","phase":"NA","title":"Compassionate Administration of ZVS101e Injection for Extended Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"Chigenovo Co., Ltd","startDate":"2026-03","conditions":"Patients With Bietti Crystalline Corneoretinal Dystrophy (Carrying Biallelic CYP4V2 Mutations)","enrollment":32},{"nctId":"NCT06743646","phase":"PHASE3","title":"Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy","status":"RECRUITING","sponsor":"Chigenovo Co., Ltd","startDate":"2024-12-27","conditions":"Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy","enrollment":62},{"nctId":"NCT05832684","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chigenovo Co., Ltd","startDate":"2023-02-20","conditions":"Bietti's Crystalline Dystrophy","enrollment":24},{"nctId":"NCT04722107","phase":"EARLY_PHASE1","title":"Safety Study of rAAV2/8-hCYP4V2 in Patients With Bietti's Crystalline Dystrophy (BCD)","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2021-04-21","conditions":"Bietti's Crystalline Dystrophy","enrollment":12},{"nctId":"NCT05714904","phase":"EARLY_PHASE1","title":"Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-09-23","conditions":"Bietti's Crystalline Dystrophy","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rAAV2/8-hCYP4V2","rAAV8-hCYP4V2","AAV8-hCYP4V2","AAV2/8-hCYP4V2","Puliretgene parvec"],"phase":"phase_3","status":"active","brandName":"ZVS101e","genericName":"ZVS101e","companyName":"Peking University Third Hospital","companyId":"peking-university-third-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ZVS101e is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}